ClinicalTrials.gg
WithdrawnNCT06104683Updated Mar 27, 2024

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

A Phase 2 interventional study of Placebo and Pirtobrutinib in Relapsing Multiple Sclerosis and Multiple Sclerosis, sponsored by Loxo Oncology, Inc.. Withdrawn at 4 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor Decision: The trial has been withdrawn with no plans to continue development.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
858th of 879
0 · median 50
Started
2024
with 56 others
Phase 2
139 of 1,192
20 open now
Registered
1,013th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 858th largest by enrollment of the 879 interventional ones that give a count, is one of 57 that started in 2024, is one of 139 in phase 2, and was the 1,013th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

03

Conditions studied

  • Relapsing Multiple Sclerosis
  • Multiple Sclerosis

Browse trials for

Keywords

  • Relapsing Forms Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have been diagnosed with relapsing MS
  • Participants must have one of the following

    1. at least 1 documented relapse within the previous year, or
    2. at least 2 documented relapse within the previous 2 years, or
    3. at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have had a diagnosis of primary progressive MS
  • Have a history of another neurological disease
  • Had a relapse of MS within 30 days prior to randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pirtobrutinib Dose 1

    Participants will receive pirtobrutinib orally.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib Dose 2

    Participants will receive pirtobrutinib orally.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib Dose 3

    Participants will receive pirtobrutinib orally.

    Drug: Pirtobrutinib

  • Placebo comparator
    Placebo

    Participants will receive placebo orally.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Administered orally

  • Administered orally

    Also known as: LY3527727

06

What researchers measure

Primary outcomes

  1. New T1 Gadolinium (Gd)-enhancing Lesions on Brain Magnetic Resonance Imaging (MRI) Per Scan

    Time frame: Week 8 and Week 12

  2. Number of New and/or Enlarging T2 Lesions

    Time frame: Week 12

Secondary outcomes

  1. Total Number of T1 Gd-Enhancing Lesions Per Scan

    Time frame: Week 8 and Week 12

  2. Total Number of Gd-Enhancing Lesions Per Scan

    Time frame: Week 8 and Week 12

  3. Pharmacokinetics (PK): Plasma Concentration of Pirtobrutinib

    Time frame: Baseline to Week 12

07

Study locations

4 sites
  • University of South Florida
    Tampa, Florida 33612, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Swedish Medical Center-501 E Hampden Ave
    Seattle, Washington 98122-5698, United States
  • Caribbean Center For Clinical Research Inc
    Guaynabo, 969, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for Jan 2026, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 27, 2023
StartEst.
May 1, 2024
Primary completionEst.
Jan 16, 2026
CompletionEst.
Feb 13, 2026
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06104683
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
May 1, 2024 (estimated)
Primary completion
Jan 16, 2026 (estimated)
Completion
Feb 13, 2026 (estimated)
Last update
Mar 27, 2024

Study contacts

1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion